NEWS DETAIL

MSD K.K. Receives Manufacturing and Marketing Approval of LYFNUA Tablets, World's First Selective P2X3 Receptor Antagonist for the Treatment of Chronic Cough

MSD K.K. (head office: Chiyoda-ku, Tokyo; Representative Director and President: Kyle Tattle; “MSD”) received on January 20 approval in Japan to manufacture and market Lyfnua® Tablets 45 mg (gefapixant citrate), a selective P2X3 receptor antagonist for the treatment of cough. 



Lyfnua® Tablets will be distributed solely by KYORIN Pharmaceutical Co., Ltd. (head office: Chiyoda-ku, Tokyo; President and CEO: Shigeru Ogihara; "KYORIN"), a subsidiary of KYORIN Holdings, Inc. (head office: Chiyoda-ku, Tokyo; President and CEO: Yutaka Ogihara), under an exclusive distribution agreement with MSD's affiliate company.




As the world's first approved selective P2X3 receptor antagonist, Lyfnua® Tablets inhibit extracellular ATP signaling via P2X3 receptors found on vagal C fibers in the airway and reduce sensory nerve activation and cough. It is indicated for refractory chronic cough.




MSD will continue to develop innovative medicines and vaccines that address unmet medical needs and invent for life. 




KYORIN will expand its product portfolio in its strategic respiratory field by exclusively distributing Lyfnua® Tablets, aiming to further increase its presence in this area and contribute to the treatment of chronic cough. 





Lyfnua® Tablets 45 mg, selective P2X3 receptor antagonist for the treatment of cough
























































 

Trade name



 



Lyfnua® Tablets 45 mg


 

 



 



 


 

Generic name



 



Gefapixant citrate


 

 



 



 


 

Indications



 



Refractory chronic cough


 

 



 



 


 

Dosage



and



Normally for adults, 45 mg of gefapixant is administered orally


 

twice daily.


 

administration



 


 

 



 


 

 



 


 

Application date



February 26, 2021


 

 



 



 


 

Approved date



 



January 20, 2022